|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
FY2021
12 months to Dec 31, 2021
|
FY2020
12 months to Dec 31, 2020
|
FY2019
12 months to Dec 31, 2019
|
|
|---|---|---|---|---|---|
| Revenues, net | |||||
| Cost of revenues | |||||
| Gross profit | |||||
| Operating expenses: | |||||
| Sales and marketing | |||||
| Research and development | |||||
| General and administrative | |||||
| Impairment loss on long-lived assets | |||||
| Total operating expenses | |||||
| Loss from operations | |||||
| Other income, net | |||||
| Loss before provision for (benefit from) income taxes | |||||
| Income tax benefit, net | |||||
| Net loss | |||||
| Foreign currency translation adjustments | |||||
| Comprehensive loss | |||||
| Net loss per share available to common stockholders, basic and diluted | |||||
| Weighted-average shares used to compute net loss per share available to common stockholders, basic and diluted | |||||
| Stock-based compensation expense | |||||
| Cost of Revenues | |||||
| Sales and Marketing | |||||
| Research and Development | |||||
| General and Administrative | |||||
| Total stock-based compensation expense | |||||
| Amortization of intangible assets | |||||
| Total amortization of intangible assets | |||||
| Restructuring related expenses | |||||
| Cost of Revenues | |||||
| Sales and Marketing | |||||
| Research and Development | |||||
| General and Administrative | |||||
| Total restructuring related expenses | |||||
| Net loss per share available to common stockholders, basic | |||||
| Net loss per share available to common stockholders, diluted | |||||
| Weighted-average shares used to compute net loss per share available to common stockholders, basic | |||||
| Weighted-average shares used to compute net loss per share available to common stockholders, diluted | |||||
Loading...